Matrix metalloproteinases (MMPs) such as MMP13 promote tumour growth and progression by mediating extracellular matrix (ECM) reorganization and regulating the biological activity of cytokines[3]. MMP13 is a vital component for chondrocyte and osteoblast maturation, and is aberrantly expressed in numerous disease states. At the transcriptional level, MMP13 is controlled by many different growth factors and hormones. Most notably, MMP13 is regulated by the vitamin D hormone (1,25(OH)2D3), parathyroid hormone (PTH), and several cytokines[4]. CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs[5]. CL-82198 (10 μM; 24 hours) significantly reduces LS174 cell migration[6]. CL-82198 decreases CTGF and TGF-β1 protein levels in hepatic stellate cells[7]. CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression. CL82198 (1-10 mg/kg; i.p.; every other day for 12 weeks) prevents and decelerates MLI-induced osteoarthritis progression[8].
搜索
